RE: Unique opportunity5 Dec 2023 08:50
We know the platform works.
We know dox is delivered to tumours at therapeutic levels.
We know safety and tolerability is exceptional.
We know there have been early signs of efficacy with STS (which will be the target).
We know there have been signs of efficacy with other indications.
We know that it's not just the company telling us this, it's been verified by the main cancer centres in the UK and US and approved by the FDA and MHRA to continue at double the standard dose of Dox.
We now know next Wednesday that we will have the data to review next Wednesday. What's not to like.